CN116286643A - Method for efficiently inducing human cells to reprogram into neuron cells in vitro - Google Patents
Method for efficiently inducing human cells to reprogram into neuron cells in vitro Download PDFInfo
- Publication number
- CN116286643A CN116286643A CN202310394174.XA CN202310394174A CN116286643A CN 116286643 A CN116286643 A CN 116286643A CN 202310394174 A CN202310394174 A CN 202310394174A CN 116286643 A CN116286643 A CN 116286643A
- Authority
- CN
- China
- Prior art keywords
- cells
- medium
- induction
- neuron
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002569 neuron Anatomy 0.000 title claims abstract description 85
- 238000000034 method Methods 0.000 title claims abstract description 36
- 210000005260 human cell Anatomy 0.000 title claims abstract description 17
- 230000001939 inductive effect Effects 0.000 title claims abstract description 17
- 238000000338 in vitro Methods 0.000 title claims abstract description 14
- 230000006698 induction Effects 0.000 claims abstract description 48
- 230000014509 gene expression Effects 0.000 claims abstract description 24
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 23
- 102100025423 Bone morphogenetic protein receptor type-1A Human genes 0.000 claims abstract description 13
- 101000934638 Homo sapiens Bone morphogenetic protein receptor type-1A Proteins 0.000 claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 13
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 claims abstract description 13
- 102100034111 Activin receptor type-1 Human genes 0.000 claims abstract description 11
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 claims abstract description 11
- 238000003209 gene knockout Methods 0.000 claims abstract description 7
- 210000002950 fibroblast Anatomy 0.000 claims abstract description 6
- 239000002609 medium Substances 0.000 claims description 40
- -1 small molecule compounds Chemical class 0.000 claims description 35
- 230000008672 reprogramming Effects 0.000 claims description 26
- 239000001963 growth medium Substances 0.000 claims description 17
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 14
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 14
- 239000003112 inhibitor Substances 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- 210000001082 somatic cell Anatomy 0.000 claims description 12
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 12
- 230000009207 neuronal maturation Effects 0.000 claims description 11
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 7
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 6
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 6
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims description 6
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 6
- 229930182555 Penicillin Natural products 0.000 claims description 6
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 6
- 229940049954 penicillin Drugs 0.000 claims description 6
- 229960005322 streptomycin Drugs 0.000 claims description 6
- CDOVNWNANFFLFJ-UHFFFAOYSA-N 4-[6-[4-(1-piperazinyl)phenyl]-3-pyrazolo[1,5-a]pyrimidinyl]quinoline Chemical compound C1CNCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C=2C3=CC=CC=C3N=CC=2)C=C1 CDOVNWNANFFLFJ-UHFFFAOYSA-N 0.000 claims description 5
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims description 5
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 238000011081 inoculation Methods 0.000 claims description 5
- 229940126654 ALK2 inhibitor Drugs 0.000 claims description 3
- 239000001569 carbon dioxide Substances 0.000 claims description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 3
- 230000000392 somatic effect Effects 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 2
- 230000002500 effect on skin Effects 0.000 claims 1
- 241000282414 Homo sapiens Species 0.000 abstract description 22
- 230000009471 action Effects 0.000 abstract description 11
- 238000001727 in vivo Methods 0.000 abstract description 5
- 230000004770 neurodegeneration Effects 0.000 abstract description 5
- 208000015122 neurodegenerative disease Diseases 0.000 abstract description 5
- 230000035755 proliferation Effects 0.000 abstract 2
- 230000008844 regulatory mechanism Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 21
- 230000001537 neural effect Effects 0.000 description 21
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 18
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 17
- 210000001626 skin fibroblast Anatomy 0.000 description 16
- 239000000427 antigen Substances 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 239000003550 marker Substances 0.000 description 13
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 11
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 11
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 11
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 11
- 238000010166 immunofluorescence Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 10
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 10
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 10
- 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 10
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 9
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 9
- 230000000903 blocking effect Effects 0.000 description 9
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 8
- 102100022086 GRB2-related adapter protein 2 Human genes 0.000 description 7
- 101710181935 Phosphate-binding protein PstS 1 Proteins 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 229930040373 Paraformaldehyde Natural products 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 239000012190 activator Substances 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 229920002866 paraformaldehyde Polymers 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 239000012825 JNK inhibitor Substances 0.000 description 4
- 239000012826 P38 inhibitor Substances 0.000 description 4
- 210000001130 astrocyte Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- XHBVYDAKJHETMP-UHFFFAOYSA-N dorsomorphin Chemical compound C=1C=C(C2=CN3N=CC(=C3N=C2)C=2C=CN=CC=2)C=CC=1OCCN1CCCCC1 XHBVYDAKJHETMP-UHFFFAOYSA-N 0.000 description 4
- 230000002222 downregulating effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001976 enzyme digestion Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000003208 gene overexpression Methods 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 230000004911 positive regulation of CREB transcription factor activity Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 241000283074 Equus asinus Species 0.000 description 3
- 229940118135 JNK inhibitor Drugs 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000003125 immunofluorescent labeling Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- DMRMZQATXPQOTP-GWTDSMLYSA-M sodium;(4ar,6r,7r,7as)-6-(6-amino-8-bromopurin-9-yl)-2-oxido-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol Chemical compound [Na+].C([C@H]1O2)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1Br DMRMZQATXPQOTP-GWTDSMLYSA-M 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 3
- XCPPIJCBCWUBNT-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)-2-[2-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]pyrimidin-4-yl]acetonitrile Chemical compound N=1C2=CC=CC=C2SC=1C(C#N)C(N=1)=CC=NC=1OCC(C=C1)=CC=C1CN1CCOCC1 XCPPIJCBCWUBNT-UHFFFAOYSA-N 0.000 description 2
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 101150041215 JNK gene Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- CJGYSWNGNKCJSB-YVLZZHOMSA-N bucladesine Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-N 0.000 description 2
- 229960005263 bucladesine Drugs 0.000 description 2
- IBGLGMOPHJQDJB-IHRRRGAJSA-N chembl1950289 Chemical compound C1C[C@@H](O)CC[C@@H]1NC1=NC=C(N=C(NC=2C(=CC(F)=CC=2F)F)N2[C@@H]3COCC3)C2=N1 IBGLGMOPHJQDJB-IHRRRGAJSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 210000002503 granulosa cell Anatomy 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- CLLFEJLEDNXZNR-UUOKFMHZSA-N (4ar,6r,7r,7as)-6-(6-amino-8-chloropurin-9-yl)-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1Cl CLLFEJLEDNXZNR-UUOKFMHZSA-N 0.000 description 1
- BHUXVRVMMYAXKN-UHFFFAOYSA-N 1-[4-[6-methyl-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl]phenyl]piperazine Chemical compound COC1=C(OC)C(OC)=CC(C=2C(=NC=C(C=2)C=2C=CC(=CC=2)N2CCNCC2)C)=C1 BHUXVRVMMYAXKN-UHFFFAOYSA-N 0.000 description 1
- YSYIWCNPSZNNKW-UHFFFAOYSA-N 11-nitroso-10h-indeno[1,2-b]quinoxaline Chemical compound C1=CC=C[C]2N[C]3C(N=O)=C(C=CC=C4)C4=C3N=C21 YSYIWCNPSZNNKW-UHFFFAOYSA-N 0.000 description 1
- XLGSEOAVLVTJDH-UHFFFAOYSA-N 12-(1-adamantylcarbamoylamino)dodecanoic acid Chemical compound C1C(C2)CC3CC2CC1(NC(=O)NCCCCCCCCCCCC(=O)O)C3 XLGSEOAVLVTJDH-UHFFFAOYSA-N 0.000 description 1
- YSUBLPUJDOWYDP-UHFFFAOYSA-N 2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline Chemical compound NC1=CC(OCC)=CC=C1OC(C=C1)=CC=C1OCC1=CC(F)=CC=C1F YSUBLPUJDOWYDP-UHFFFAOYSA-N 0.000 description 1
- GJFCSAPFHAXMSF-UXBLZVDNSA-N 3-[[(e)-4-(dimethylamino)but-2-enoyl]amino]-n-[3-methyl-4-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide Chemical compound CN(C)C\C=C\C(=O)NC1=CC=CC(C(=O)NC=2C=C(C)C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)=CC=2)=C1 GJFCSAPFHAXMSF-UXBLZVDNSA-N 0.000 description 1
- GDTQLZHHDRRBEB-UHFFFAOYSA-N 4-[5-(cyclopropylcarbamoyl)-2-methylanilino]-5-methyl-n-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide Chemical compound C12=C(C)C(C(=O)NCCC)=CN2N=CN=C1NC(C(=CC=1)C)=CC=1C(=O)NC1CC1 GDTQLZHHDRRBEB-UHFFFAOYSA-N 0.000 description 1
- LKOFXMLMYKWELM-UHFFFAOYSA-N 5,11-dimethyl-2-[(1-piperidin-4-ylpyrazol-4-yl)amino]pyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound N1=C2N(C)C3=CC=CC=C3C(=O)N(C)C2=CN=C1NC(=C1)C=NN1C1CCNCC1 LKOFXMLMYKWELM-UHFFFAOYSA-N 0.000 description 1
- NARMJPIBAXVUIE-UHFFFAOYSA-N 5-[2-tert-butyl-4-(4-fluorophenyl)-1h-imidazol-5-yl]-3-(2,2-dimethylpropyl)imidazo[4,5-b]pyridin-2-amine;methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.N1=C2N(CC(C)(C)C)C(N)=NC2=CC=C1C=1N=C(C(C)(C)C)NC=1C1=CC=C(F)C=C1 NARMJPIBAXVUIE-UHFFFAOYSA-N 0.000 description 1
- BBDGBGOVJPEFBT-UHFFFAOYSA-N 5-[6-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline Chemical compound C1CNCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C=2C3=CC=CN=C3C=CC=2)C=C1 BBDGBGOVJPEFBT-UHFFFAOYSA-N 0.000 description 1
- KKYABQBFGDZVNQ-UHFFFAOYSA-N 6-[5-[(cyclopropylamino)-oxomethyl]-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)-3-pyridinecarboxamide Chemical compound CC1=C(F)C=C(C(=O)NC2CC2)C=C1C1=CC=C(C(=O)NCC(C)(C)C)C=N1 KKYABQBFGDZVNQ-UHFFFAOYSA-N 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- JMIFGARJSWXZSH-UHFFFAOYSA-N DMH1 Chemical compound C1=CC(OC(C)C)=CC=C1C1=CN2N=CC(C=3C4=CC=CC=C4N=CC=3)=C2N=C1 JMIFGARJSWXZSH-UHFFFAOYSA-N 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- KGPGFQWBCSZGEL-ZDUSSCGKSA-N GSK690693 Chemical compound C=12N(CC)C(C=3C(=NON=3)N)=NC2=C(C#CC(C)(C)O)N=CC=1OC[C@H]1CCCNC1 KGPGFQWBCSZGEL-ZDUSSCGKSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- HEKAIDKUDLCBRU-UHFFFAOYSA-N N-[4-[2-ethyl-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]benzamide Chemical compound S1C(CC)=NC(C=2C=C(C)C=CC=2)=C1C(C=1)=CC=NC=1NC(=O)C1=CC=CC=C1 HEKAIDKUDLCBRU-UHFFFAOYSA-N 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- QHKYPYXTTXKZST-UHFFFAOYSA-N SB-202190 Chemical compound C1=CC(O)=CC=C1C1=NC(C=2C=CC(F)=CC=2)=C(C=2C=CN=CC=2)N1 QHKYPYXTTXKZST-UHFFFAOYSA-N 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229950006785 bentamapimod Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- HPSWAEGGWLOOKT-VUNDNAJOSA-N cis-Mulberroside A Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C=C1O)=CC=C1\C=C\C1=CC(O)=CC(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 HPSWAEGGWLOOKT-VUNDNAJOSA-N 0.000 description 1
- HPSWAEGGWLOOKT-UHFFFAOYSA-N cis-mulberroside A Natural products OC1C(O)C(O)C(CO)OC1OC(C=C1O)=CC=C1C=CC1=CC(O)=CC(OC2C(C(O)C(O)C(CO)O2)O)=C1 HPSWAEGGWLOOKT-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 229950005210 colforsin Drugs 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- MVCOAUNKQVWQHZ-UHFFFAOYSA-N doramapimod Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 MVCOAUNKQVWQHZ-UHFFFAOYSA-N 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000011013 endotoxin removal Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- CHSDJDLAKKAWCI-UHFFFAOYSA-N hth-01-015 Chemical compound N1=C2N(C)C3=CC4=CC=CC=C4C=C3C(=O)N(C)C2=C(C)N=C1NC(=C1)C=NN1C1CCNCC1 CHSDJDLAKKAWCI-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- JYYLVUFNAHSSFE-UHFFFAOYSA-N pamapimod Chemical compound O=C1N(C)C2=NC(NC(CCO)CCO)=NC=C2C=C1OC1=CC=C(F)C=C1F JYYLVUFNAHSSFE-UHFFFAOYSA-N 0.000 description 1
- 229950001749 pamapimod Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229950002902 tanzisertib Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- UZKQTCBAMSWPJD-UQCOIBPSSA-N trans-Zeatin Natural products OCC(/C)=C\CNC1=NC=NC2=C1N=CN2 UZKQTCBAMSWPJD-UQCOIBPSSA-N 0.000 description 1
- UZKQTCBAMSWPJD-FARCUNLSSA-N trans-zeatin Chemical compound OCC(/C)=C/CNC1=NC=NC2=C1N=CN2 UZKQTCBAMSWPJD-FARCUNLSSA-N 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/09—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from epidermal cells, from skin cells, from oral mucosa cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides a method for efficiently inducing human cells to reprogram into neuron cells in vitro, which inhibits the expression of ALK2 and ALK3 loci through small molecular compounds, gene interference and gene knockout. The induction small molecular compound is single and safe, has short induction time, high induction efficiency, definite induction action site and gene and clear molecular regulation mechanism, can be applied to clinical treatment of human neurodegenerative diseases, and provides a safer and more efficient treatment means for the treatment of the neurodegenerative diseases. Because the neurons have no division proliferation capacity, the patent can be used for inducing the fibroblasts with division proliferation capacity in vitro and in vivo, and a large number of induced neurons can be obtained in vitro and in vivo continuously.
Description
Technical Field
The invention belongs to the field of stem cells, and particularly relates to a method for efficiently inducing human cells to reprogram into neuron cells in vitro.
Background
Reprogramming terminally differentiated somatic cells into neurons has been achieved in a variety of species such as humans, mice, and the like, using transfection of exogenous transcription factors, and induction methods such as small molecule compound combinations. The 2015 Pei Gang group reports the reprogramming of fibroblasts into neurons in alzheimer's patients using a combination of 7 small molecule compounds. Human astrocytes were induced into neurons by Brueckner B et al 2005 using a combination of 6 small molecule compounds. These small molecule compounds inhibit the expression of non-neuronal genes, promote the expression of neuronal specific genes, and finally obtain mature functional neurons by prolonged culture of induced cells.
Although the existing methods for inducing neurons have a plurality of types, the methods have the defects of overlong induction time (20-30 days), low induction efficiency (10-30%), excessively complex method, high potential biosafety risk and the like. In terms of application of cell therapy, the prior art can greatly reduce the effect of clinical therapy due to excessive induction factors, overlong induction time and low efficiency, and increase potential side effects of therapy and worry about biosafety. In terms of mechanism, the prior art uses the combined action of a plurality of small molecule compounds, the signal paths of the action are staggered, the action sites are complex, and how the transformation of somatic cells into neuronal fate is determined cannot be accurately revealed. No technology is currently available to elucidate the mechanism by which somatic cells can be reprogrammed to neuronal cells using a single small molecule compound, nor is it fully elucidate the mechanism by which somatic cells are reprogrammed to neurons.
Whereas the induction system of the present invention allows reprogramming somatic cells to TUJ1 positive neuronal cells (up to about 80% positive rate) within two days using only a single small molecule compound or the regulatory effect of a single gene. More importantly, the methods of small molecule compound combinations used by the predecessor have failed to elucidate the mechanism of cell fate conversion. Our findings clearly illustrate the molecular regulatory pathways of reprogramming human cells to neuronal cells, confirming that the regulatory effects of a single small molecule compound or a single gene can induce reprogramming human cells to neuronal cells. In addition, no one has reported the key regulatory sites of reprogramming mentioned in the present invention.
Disclosure of Invention
In view of this, the present invention is directed to a method for efficiently inducing reprogramming of human cells into neuronal cells in vitro, so as to overcome the defects of the prior art, and determine that the regulation effect of a single small molecule compound or a single gene can induce reprogramming of human cells into neuronal cells.
A method for efficiently inducing human cells to reprogram into neuron cells increases cAMP concentration or up-regulates expression of any site of PKA and CREB or inhibits expression of any site of AMPK, ALK2, ALK3, P38 and JNK.
Preferably, small molecule compounds, including one or more of cAMP activators, cAMP analogs, PKA activators, CREB activators, AMPK inhibitors, ALK2 inhibitors, ALK3 inhibitors, P38 inhibitors, JNK inhibitors, are used, preferably, to increase the concentration of cAMP or to up-regulate the expression of any site of PKA, CREB, or to inhibit the expression of any site of AMPK, ALK2, ALK3, P38, JNK, or small molecule compounds, gene interference, gene knockout or gene overexpression.
The human cells are induced to reprogram into various action sites of neuron cells and small molecule compounds acting on the sites, wherein the action sites comprise cAMP (increasing concentration), PKA (activating/up-regulating expression), CREB (activating/up-regulating expression), ALK2/3 (inhibiting/down-regulating expression), JNK (inhibiting/down-regulating expression), P38 (inhibiting/down-regulating expression) and AMPK (inhibiting/down-regulating expression). Any single small molecule compound including, but not limited to, cAMP/PKA/CREB activator (Forskolin/Colforsin/8-Bromo-cAMP/Dibutyryl-cAMP (Bucladesine)/cAMP and the like), ALK2/3 inhibitor (LDN-193189/LDN-193189-2 HCl/K02288/LDN-212854/LDN-214117/ML347/DMH 1/and the like), JNK inhibitor (SP 600125/Resveratrol/JNK-IN-8/JNK-InbitorVIII/DB 07268/IQ-1S/bentamap imod (AS 602801)/Tanzisertib (CC-930)/BI-78D 3/JNK InbitorIX/Uithin B/Loureireib/falcarindi/Culcipariib/Mulboroside A/Trans-ZeatinAstragaloside IV and the like, P38 inhibitors (SB 203580/Doramapimod (BIRB 796)/SB 202190 (FHPI)/Ralimetinib dimesylate/VX-702/PH-797804/VX-745/TAK-715/PD169316/TA-02/SD0006/Pamapimod/BMS-582949/SB 239063/Losmaapimod (GW 856553X)/Sepinone-L/SEA 0400/AUDA/Praeroup torina/Mulberroside A/UM-164/Trans-Zeatin/3' -hydrooxymatrilbene/P exmetinib (ARRY-614) and the like), AMPK inhibitors (Dorsomophin/WZ 4003/ON123300/HTH-01-015/GSK690693/XMD-17-51/Dorsomorphin (CompoundC)/Dorsomorphin (CompoundC) 2HCl/Doxorubicin (Adriamycin) HCl, etc.) can induce human skin fibroblasts, human follicular granulosa cells, human astrocytes, and the like to reprogram functional neurons.
A second object of the present invention is to provide an induction medium for efficiently inducing reprogramming of human cells into neuronal cells, comprising a base fluid, KSR, and a small molecule compound, preferably, the small molecule compound comprises one or more of cAMP activator, cAMP analog (e.g. DBcAMP, 8-Cl-cAMP, etc.), PKA activator, CREB activator, AMPK inhibitor, ALK2 inhibitor, ALK3 inhibitor, P38 inhibitor, JNK inhibitor.
Preferably, the small molecule compound comprises Forskolin, 8-Bromo-cAMP, LDN193189, cAMP analog, SP600125, SB203580, dorsomorphin, and in the final medium, the respective concentrations are 0 to 100 μm, 0 to 500 μm, 0 to 25 μm, 0 to 10mM, 0 to 10 μm, 0 to 5 μm, 0 to 100 μm, respectively, at different concentrations of 0; preferably, the respective concentrations are 5 to 20. Mu.M, 5 to 50. Mu.M, 0.5 to 5mM, 0.5 to 5. Mu.M, 0.1 to 2.5. Mu.M, 0.5 to 20. Mu.M, respectively, in this order; more preferably, the respective concentrations are 10. Mu.M, 50. Mu.M, 2.5. Mu.M, 1mM, 1. Mu.M, 0.5. Mu.M, 10. Mu.M, respectively, in order.
Preferably, the volume ratio of the base liquid to the KSR is 80:20; preferably, the base liquid is N2B27, including KnockoutDMEM/F12, N2 (100×), neurobasal, B27 (50×), glutamine (100×); and the volume ratio of the two is 99:1:97:2:1.
A third object of the present invention is to provide the use of the induction medium described above for inducing reprogramming of somatic cells into neuronal cells in vitro and in vivo.
A fourth object of the present invention is to provide a method for in vitro induction of somatic reprogramming into neuronal cells using an induction medium, comprising the steps of:
1) Inoculating somatic cells into a culture dish, adding high-sugar DMEM+10% FBS after inoculation, placing the culture dish in an incubator with 5% carbon dioxide and humidity of 95% and 37 ℃, replacing the induction culture medium according to any one of claims 3-5 after overnight culture, and obtaining induction neurons (CiNCs) after 48h of induction culture;
2) The medium is replaced by a neuron maturation medium, the induced neurons are further matured continuously, and the neurons are replaced by the neuron maturation medium after 72 hours, so that the neurons can be cultured for a long time.
Preferably, the components of the neuronal maturation medium include DMEM/F12 and Neurobasal at a volume ratio of 1:1, 0.5% N2 (volume percent), 1% B27 (volume percent), 100 μM cAMP,20ng/mL bFGF,20ng/mL BDNF,20ng/mL GDNF,20ng/mL NT3, 100U/mL penicillin and 0.1mg/mL streptomycin.
Preferably, the composition of the neuronal medium comprises DMEM/F12 in a volume ratio of 1:1: neurobasal,0.5% N2 (volume percent), 1% B27 (volume percent), 20ng/mL bFGF,20ng/mL BDNF,20ng/mL GDNF,20ng/mL NT3, 100U/mL penicillin, and 0.1mg/mL streptomycin.
The somatic cells are derived from human, monkey or mouse; the somatic cells are skin fibroblasts, follicular granulosa cells or astrocytes.
Compared with the prior art, the method for efficiently inducing the reprogramming of the human cells into the neuron cells has the following beneficial effects:
(1) The patent fills a gap in the use of a single small molecule compound to induce reprogramming of terminally differentiated human cells into functional neurons.
(2) The patent fills a gap in regulating the expression of a single gene (PKA, CREB, JNK) to induce the reprogramming of terminally differentiated human cells into functional neurons.
(3) The present patent provides neuronal cells with a TUJ1 positive rate of about 80% with a single small molecule compound, and with an induction time of only about two days. Compared with the work of the former, the induction time is greatly shortened, and the induction efficiency is greatly improved.
(4) The patent uses the characteristics of clear action path and clear action site of single small molecular compound, and clarifies that the molecular regulation path of the whole reprogramming process of somatic cell reprogramming into neuron is cAMP-PKA-CREB-JNK and its key regulation genes are PKA, CREB and JNK. This mechanism has not been explicitly elucidated.
(5) The induction small molecular compound is single and safe, has short induction time, high induction efficiency and clear mechanism, can be applied to clinical treatment of human neurodegenerative diseases, and provides a safer and more efficient treatment means for the treatment of the neurodegenerative diseases. The patent can be used for inducing fibroblasts and astrocytes in vitro and in vivo to continuously obtain a large number of induced neurons in vitro and in vivo, so that the purpose of clinically treating neurodegenerative diseases is achieved by using regenerated induced neurons.
Drawings
The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and together with the description serve to explain the invention. In the drawings:
FIG. 1 is a time pathway of example 1 for a single small molecule compound Forskolin to induce reprogramming of human skin fibroblasts into neurons;
FIG. 2 is a graph showing the morphological change of the single small molecule compound Forskolin induced reprogramming of human skin fibroblasts into neurons of example 1;
FIG. 3 is the immunofluorescence results of example 1 for a single small molecule compound Forskolin to induce reprogramming of human skin fibroblasts into neurons;
FIG. 4 is a graph showing the results of quantitative PCR of the single small molecule compound Forskolin induced reprogramming of human skin fibroblasts into neurons of example 1;
FIG. 5 is a graph showing the effect of a small molecule compound, gene overexpression or gene knockout induction method on a single distinct site on a reprogramming control pathway.
Detailed Description
Unless defined otherwise, technical terms used in the following examples have the same meaning as commonly understood by one of ordinary skill in the art to which the present invention pertains. The test reagents used in the following examples, unless otherwise specified, are all conventional biochemical reagents; the experimental methods are conventional methods unless otherwise specified.
The present invention will be described in detail with reference to the following examples and drawings.
A method for efficiently inducing human cells to reprogram into neuron cells comprises the following steps: the concentration of cAMP is increased or the expression of any site of PKA and CREB is up-regulated or the expression of any site of AMPK, ALK2, ALK3, P38 and JNK is inhibited by using a small molecular compound, gene interference, gene knockout or gene overexpression, wherein the small molecular compound comprises one or more than two of cAMP activator, cAMP analogue, PKA activator, CREB activator, AMPK inhibitor, ALK2 inhibitor, ALK3 inhibitor, P38 inhibitor and JNK inhibitor.
1. Small molecule compound induction medium components that regulate any site of the neuronal cell reprogramming molecular pathway (cAMP, PKA, CREB, AMPK, ALK, ALK3, P38, JNK) (increase cAMP concentration or up-regulate expression of PKA, CREB or inhibit expression of AMPK, ALK2, ALK3, P38, JNK):
base liquid (N2B 27): 200mL system:
induction medium: 100mL system:
N2B2780mL
KSR (serum replacement) 20mL
The names and concentrations of the small molecule compounds are shown in tables 1 and 2.
Table 1 Induction concentration and efficiency of representative small molecule Compounds at each site of action and Gene validation of the site of action
TABLE 2 list of small molecule Compounds at each site of action
2. Neuron maturation medium composition: DMEM/F12: neurobasal=1:1 (volume ratio), 0.5% n2 (volume percent), 1% b27 (volume percent), 100 μΜ cAMP,20ng/mL bFGF,20ng/mL BDNF,20ng/mL lgdnf,20ng/mL NT3, 100U/mL penicillin and 0.1mg/mL streptomycin.
3. Neuron culture medium composition: DMEM/F12: neurobasal=1:1 (volume ratio), 0.5% n2 (volume percent), 1% b27 (volume percent), 20ng/mL bFGF,20ng/mL BDNF,20ng/mL GDNF,20ng/mL NT3, 100U/mL penicillin and 0.1mg/mL streptomycin.
4. The induction process comprises the following steps:
1. the cell inoculation density of human body is 5 multiplied by 10 by taking a 60mm culture dish as a standard 5 After inoculation, high-sugar dmem+10% fbs (fibroblast medium/FM) was added, and the mixture was placed in an incubator with 5% carbon dioxide, 95% humidity and 37 ℃ for overnight culture, and the above-mentioned neuron induction medium was replaced, and induced neurons (CiNCs) were obtained after 48 hours of induction.
2. The induced neuron obtained after 48h of induction culture is replaced by the neuron maturation medium, the further maturation of the induced neuron is further promoted, and the neuron can be cultivated for a long time after 72h of culture by replacing the neuron with the neuron medium again.
Example 1
Human skin fibroblasts (BJs) have been successfully reprogrammed into functional neurons using this method of inducing reprogramming.
The overall experimental induction is shown in figure 1.
The specific operation is as follows:
human skin fibroblasts were cultured at 5X 10 5 Is inoculated into a 60mm dish, and the neuron induction medium (N2B27+KSR+10. Mu.M Forskolin) is replaced within 24 hours of inoculation, and placed at 37℃with 5% CO 2 The incubator was incubated for 48 hours. The morphological changes of the cells during induction are shown in FIG. 2, and induced neurons (CiNCs) with a TUJ1 positive rate of 80% were obtained 48 hours after induction.
After 48 hours of induction, the neuronal maturation medium was replaced to further promote the maturation of CiNCs, and after 72 hours, the neuronal medium was replaced to allow for long-term culture.
We performed immunofluorescence detection of neuronal labeled antigen on human skin fibroblasts and cells induced by neuronal induction culture (N2B27+10. Mu.M Forskolin) for 48 hours. The method comprises the following specific steps: 4% Paraformaldehyde (PFA) cells of human skin fibroblasts, F-48h in a room temperature fixed culture plate for 30min; the blocking solution is washed for three times, and each time is washed for 5min; then adding 1% TritonX-100 permeabilized cells, and standing at room temperature for 15min; the blocking solution is washed for three times again; then adding 5% donkey serum to block the nonspecific site, and blocking for 2 hours at room temperature; washing with TBP (Triton X-BSA-PBS) three times for 5min each; adding a primary antibody, and standing at 4 ℃ for incubation overnight; the next day, the culture plate is placed under the condition of room temperature and rewarmed for 20min, then is washed by TBP for 3 times, each time is 5min, secondary antibody and Hoechst mixed solution are added in a dark place, and the culture plate is incubated for 1h at room temperature; and (3) washing the TBP solution for 3 times, and performing fluorescent microscope observation photographing experiments. Immunofluorescent staining results showed (see FIG. 3) that neuronal cells (F-48 h) were induced to express neuronal marker antigens, TUJ1, MAP2, whereas human skin fibroblasts were not.
Quantitative PCR (qPCR) detects the expression of the neuronal marker genes. The specific operation steps are as follows: (1) total RNA extraction. Discarding the culture medium, washing with PBS for three times, and adding 1ml of precooled TRIZOL ice for 5min for cleavage; 200 mu L of chloroform is added, and the mixture is vigorously shaken for 15s and placed on ice for 5min;12000r/min, centrifuging at 4 ℃ for 15min; transferring the upper water phase into precooled isopropanol, mixing, and standing on ice for 5min;12000r/min, centrifuging at 4deg.C for 10min; discarding the supernatant, adding 1mL of pre-cooled 75% ethanol, flicking the bottom of the tube with a fingertip to suspend the RNA, fully washing the RNA and the tube wall, centrifuging at 4 ℃ for 8min, and washing the RNA and the tube wall; removing supernatant, adding proper amount of DEPC water to completely dissolve RNA when the precipitate is semitransparent, taking 1 μl for purity and integrity detection, and performing reverse transcription or freezing the rest in-80deg.C refrigerator. (2) preparation of cDNA template. The Vazyme R223-01 synthesis kit was used in accordance with instructions. (3) fluorescent quantitative PCR. The procedure was followed using the Vazyme Q711-02/03 reagent. qPCR results show (FIG. 4) that compared with human skin fibroblasts (F-0 h), the expression levels of neuron-associated marker genes neuroD1, tubulin, ascl1 and the like are significantly reduced by inducing the neuronal cells (F-48 h) to highly express the fibroblast marker gene Col1A1 and the like.
Example 2
The difference from example 1 is that the neuron induction medium used is n2b27+ksr+10mcamp. Immunofluorescence assay results showed that the induced neuronal cells expressed neuronal marker antigens TUJ1, MAP2 and NeuN (see fig. 5).
Example 3
The difference from example 1 is that the neuron induction medium used is N2B27+KSR+10μM 8-Bromo-cAMP. Immunofluorescence assay results showed that the induced neuronal cells expressed neuronal marker antigens TUJ1, MAP2 and NeuN (see fig. 5).
Example 4
The difference from example 1 is that the neuron induction medium used is N2B27+KSR+10. Mu.M Dorsomorphin. Immunofluorescence assay results showed that the induced neuronal cells expressed neuronal marker antigens TUJ1, MAP2 and NeuN (see fig. 5).
Example 5
The difference from example 1 is that the neuron induction medium used is n2b27+ksr+5 μm LDN193189. Immunofluorescence assay results showed that the induced neuronal cells expressed neuronal marker antigens TUJ1, MAP2 and NeuN (see fig. 5).
Example 6
The difference from example 1 is that the neuron induction medium used is n2b27+ksr+5μ MSB203580. Immunofluorescence assay results showed that the induced neuronal cells expressed neuronal marker antigens TUJ1, MAP2 and NeuN (see fig. 5).
Example 7
The difference from example 1 is that the neuron induction medium used is n2b27+ksr+10mu MSP600125. Immunofluorescence assay results showed that the induced neuronal cells expressed neuronal marker antigens TUJ1, MAP2 and NeuN (see fig. 5).
Example 8
First, an overexpression recombinant plasmid (pLVX-PKA-IRES) of PKA gene was constructed. Extracting RNA from cells with high expression of a target gene (PKA) by adopting a Trizol method, designing a primer after reverse transcription, and amplifying the complete coding region sequence of the PKA gene by using cDNA as a template through PCR. The PCR product was then subjected to agarose electrophoresis and PKA gene fragments were excisedAnd (5) the glue blocks corresponding to the sections are subjected to glue recovery. And (3) after the gel is recovered, measuring the DNA concentration to obtain the target gene fragment. Double enzyme digestion is carried out on the over-expression empty vector (pLVX-IRES) plasmid by using restriction enzyme, agarose electrophoresis and gel recovery are carried out on the plasmid after enzyme digestion is completed, the concentration of gel recovery products is measured, and homologous recombination is carried out on the gel recovery products and PKA gene fragments. Then the recombinant product is transformed into E.coli T1 competent cells in ampicillin (Amp + ) Is spread on LB solid plate medium and placed in a 37 ℃ incubator to cause culture for 12-16 h. Picking up the monoclonal antibody in the presence of Amp + Continuous culture in LB liquid medium. And (3) performing colony PCR identification on the bacterial liquid, selecting the bacterial liquid with correct identification, extracting plasmids by using a plasmid extraction kit, and performing further enzyme digestion identification. The plasmids identified as correct were sent to the company for sequencing. And finally, carrying out amplification culture on bacterial liquid corresponding to the plasmid with correct sequencing, and extracting recombinant over-expression plasmid (pLVX-PKA-IRES) by using an endotoxin removal plasmid extraction kit.
Viral packaging and cell infection are then performed to induce neuronal transdifferentiation. Resuscitating HEK-293T cells at 37deg.C with 5% CO 2 In the incubator, when the cell confluence reaches 50% -60%, adopting a liposome transfection method to dilute Lipofectamine by using a serum-free DMEM culture medium TM 3000, and mixing thoroughly. DNA was diluted with serum-free DMEM medium (recombinant over-expression plasmid pLVX-PKA-IRES, viral packaging plasmid NRF and viral envelope plasmid VSVG=5:3:2), and P3000 was added after preparation of a DNA premix TM The reagent is fully and evenly mixed. In diluted Lipofectamine TM Diluted DNA was added to the 3000 reagent (ratio Lip3000: dna=2.5:1). Incubating at room temperature for 10min, co-transfecting HEK-293T cells with the DNA-liposome complex, culturing at 37 ℃ and 5% CO2, collecting virus supernatant after 48-72h, centrifuging at 4 ℃ and 2000r/min for 10min, and filtering with a 0.45 μm filter. The filtered virus solution and the culture medium are directly infected with human skin fibroblasts (5×10) according to a mixing ratio of 1:1 5 ) After 2 days, the medium (N2B27+KSR) was changed, and the culture was continued in a 5% CO2 incubator at 37℃for 2 days. Then, the culture medium is replaced by a neuron maturation medium to be continued for 3 days, so that the CiNCs maturation is further promoted. Finally, the culture medium is replaced by a neuron culture medium, and long-time culture can be performedAnd (5) nourishing.
And finally, verifying the induced neurons. We performed immunofluorescence detection of neuronal labeled antigens on the neuronal cells induced as described above. The method comprises the following specific steps: 4% Paraformaldehyde (PFA) cells of human skin fibroblasts, F-48h in a room temperature fixed culture plate for 30min; the blocking solution is washed for three times, and each time is washed for 5min; then adding 1% TritonX-100 permeabilized cells, and standing at room temperature for 15min; the blocking solution is washed for three times again; then adding 5% donkey serum to block the nonspecific site, and blocking for 2 hours at room temperature; washing with TBP (Triton X-BSA-PBS) three times for 5min each; adding a primary antibody, and standing at 4 ℃ for incubation overnight; the next day, the culture plate is placed under the condition of room temperature and rewarmed for 20min, then is washed by TBP for 3 times, each time is 5min, secondary antibody and Hoechst mixed solution are added in a dark place, and the culture plate is incubated for 1h at room temperature; and (3) washing the TBP solution for 3 times, and performing fluorescent microscope observation photographing experiments. Immunofluorescent staining results showed (see fig. 5), that neuronal cells were induced to express neuronal marker antigens, TUJ1, MAP2 and NeuN.
Example 9
The difference from example 8 is that the overexpressed gene is CREB. Immunofluorescence assay results showed that the induced neuronal cells expressed neuronal marker antigens TUJ1, MAP2 and NeuN (see fig. 5).
Example 10
Firstly, constructing a JNK gene knockout recombinant plasmid (U6-sgJNK-EF 1a-Cas9-FLAG-P2A-P uro). JNK gene exons were selected, targeted sgJNK was designed using MIT Zhang Feng laboratory sgRNA design tools, and the sticky ends of restriction enzymes were added to the sgJNK primers to facilitate ligation with empty vector (U6-sgRNA-EF 1a-Cas 9-FLAG-P2A-puro). The primer dry powder synthesized by the company is diluted to the working concentration by ddH2O, and an annealing system is configured for annealing. Linearizing empty vector by restriction endonuclease followed by insertion of sgJNK, ligation followed by transformation of competent escherichia coli, and transformation of the empty vector with ampicillin (Amp + ) Is spread on LB solid plate medium and placed in a 37 ℃ incubator to cause culture for 12-16 h. The monoclonal is picked up and cultured continuously in LB liquid medium containing Amp+. Performing colony PCR identification on the bacterial liquid, and selecting plasmid extraction test for the bacterial liquid with correct identificationThe plasmid extracted by the kit is further subjected to enzyme digestion identification, and the plasmid with correct identification is sent to a company for sequencing. And finally, performing amplification culture on bacterial liquid corresponding to the plasmid with correct sequencing, and extracting the plasmid containing the sgJNK expression original by using an endotoxel removal extraction kit for transfecting cells.
Packaging and cell infection of JNK knockout virus were then performed. Resuscitating HEK-293T cells at 37deg.C with 5% CO 2 In the incubator, when the cell confluence reaches 50% -60%, adopting a liposome transfection method to dilute Lipofectamine by using a serum-free DMEM culture medium TM 3000, and mixing thoroughly. DNA was diluted with serum-free DMEM medium (Cas 9 plasmid, virus packaging plasmid psPAX2 and pmdg2=5:3:2), prepared as a DNA premix followed by addition of P3000 TM The reagent is fully and evenly mixed. In diluted Lipofectamine TM Diluted DNA was added to the 3000 reagent (ratio Lip3000: dna=2.5:1). Incubating at room temperature for 10min, co-transfecting HEK-293T cells with the DNA-liposome complex, culturing at 37 ℃ and 5% CO2, collecting virus supernatant after 48-72h, centrifuging at 4 ℃ and 2000r/min for 10min, and filtering with a 0.45 μm filter. The filtered virus solution and the culture medium are directly infected with human skin fibroblasts (5×10) according to a mixing ratio of 1:1 5 ) After 2 days, the medium (N2B27+KSR) was changed, and the culture was continued in a 5% CO2 incubator at 37℃for 2 days. Then, the culture medium is replaced by a neuron maturation medium to be continued for 3 days, so that the CiNCs maturation is further promoted. Finally, the culture medium is replaced by a neuron culture medium, so that long-time culture can be performed.
And finally, verifying the induced neurons. We performed immunofluorescence detection of neuronal labeled antigens on the neuronal cells induced as described above. The method comprises the following specific steps: 4% Paraformaldehyde (PFA) cells of human skin fibroblasts, F-48h in a room temperature fixed culture plate for 30min; the blocking solution is washed for three times, and each time is washed for 5min; then adding 1% TritonX-100 permeabilized cells, and standing at room temperature for 15min; the blocking solution is washed for three times again; then adding 5% donkey serum to block the nonspecific site, and blocking for 2 hours at room temperature; washing with TBP (Triton X-BSA-PBS) three times for 5min each; adding a primary antibody, and standing at 4 ℃ for incubation overnight; the next day, the culture plate is placed under the condition of room temperature and rewarmed for 20min, then is washed by TBP for 3 times, each time is 5min, secondary antibody and Hoechst mixed solution are added in a dark place, and the culture plate is incubated for 1h at room temperature; and (3) washing the TBP solution for 3 times, and performing fluorescent microscope observation photographing experiments. Immunofluorescent staining results showed (see fig. 5), that neuronal cells were induced to express neuronal marker antigens, TUJ1, MAP2 and NeuN.
The results of these examples demonstrate that either a single small molecule compound or a gene knockout/overexpression control signal pathway (cAMP, PKA, CREB, AMPK, ALK, ALK3, P38, JNK) can induce efficient reprogramming of human cells into neuronal cells.
The foregoing description of the preferred embodiments of the invention is not intended to be limiting, but rather is intended to cover all modifications, equivalents, alternatives, and improvements that fall within the spirit and scope of the invention.
Claims (10)
1. A method for efficiently inducing human cells to reprogram into neuron cells in vitro, which is characterized in that: inhibiting expression of any site of ALK2 and ALK3, wherein the somatic cell is a dermal fibroblast.
2. The method according to claim 1, characterized in that: expression of the ALK2 site is inhibited using small molecule compounds, gene interference, gene knockout, preferably small molecule compounds including ALK2 inhibitors or ALK3 inhibitors.
3. The method according to claim 1, characterized in that: in vitro efficient induction of somatic reprogramming into neuronal cells is performed using an induction medium comprising a base fluid, KSR, and a small molecule compound, preferably comprising an ALK2 inhibitor or an ALK3 inhibitor.
4. A method according to claim 3, characterized in that: the small molecule compound includes LDN193189 and has a concentration of 0-25. Mu.M, preferably 0.5-5. Mu.M, in the final medium.
5. The method according to claim 4, wherein: the concentration of the small molecule compound was 2.5. Mu.M.
6. A method according to claim 3, characterized in that: the volume ratio of the base solution to the KSR is 80:20.
7. The method according to claim 6, wherein: the base liquid is N2B27, including Knockout DMEM/F12, N2 (100×), neurobasal, B27 (50×), and Glutamine (100×); and the volume ratio of the two is 99:1:97:2:1.
8. A method of inducing somatic reprogramming into neuronal cells in vitro using an induction medium, characterized in that: the method comprises the following steps:
1) Inoculating somatic cells into a culture dish, adding high-sugar DMEM+10% FBS after inoculation, placing the culture dish in an incubator with 5% carbon dioxide and humidity of 95%, and at 37 ℃, and replacing an induction culture medium after overnight culture, wherein the induction culture medium comprises a base solution, KSR and small molecular compounds, the small molecular compounds comprise LDN193189, the concentration of the small molecular compounds in the final culture medium is 0-25 mu M, the volume ratio of the base solution to the KSR is 80:20, the base solution is N2B27, and the base solution comprises Knockout DMEM/F12, N2 (100×), neurobasal, B27 (50×), and Glutamine (100×); and the volume ratio of the two is 99:1:97:2:1, and induced neurons (CiNCs) are obtained after 48h of induced culture;
2) The medium is replaced by a neuron maturation medium, the induced neurons are further matured continuously, and the neurons are replaced by the neuron maturation medium after 72 hours, so that the neurons can be cultured for a long time.
9. The method according to claim 8, wherein: the components of the neuron maturation medium include DMEM/F12 and Neurobasal at a volume ratio of 1:1, 0.5% N2 (volume percent), 1% B27 (volume percent), 100 μM cAMP,20ng/mL bFGF,20ng/mL BDNF,20ng/mL GDNF,20ng/mL NT3, 100U/mL penicillin and 0.1mg/mL streptomycin.
10. The method according to claim 9, wherein: the components of the neuron culture medium include DMEM/F12 in a volume ratio of 1:1: neurobasal,0.5% N2 (volume percent), 1% B27 (volume percent), 20ng/mL bFGF,20ng/mL BDNF,20ng/mL GDNF,20ng/mL NT3, 100U/mL penicillin, and 0.1mg/mL streptomycin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310394174.XA CN116286643A (en) | 2021-03-26 | 2021-03-26 | Method for efficiently inducing human cells to reprogram into neuron cells in vitro |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110326257.6A CN113278585B (en) | 2021-03-26 | 2021-03-26 | Method for in vitro induction of reprogramming of human cells into neuron cells |
CN202310394174.XA CN116286643A (en) | 2021-03-26 | 2021-03-26 | Method for efficiently inducing human cells to reprogram into neuron cells in vitro |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110326257.6A Division CN113278585B (en) | 2021-03-26 | 2021-03-26 | Method for in vitro induction of reprogramming of human cells into neuron cells |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116286643A true CN116286643A (en) | 2023-06-23 |
Family
ID=77276022
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310394175.4A Pending CN116179489A (en) | 2021-03-26 | 2021-03-26 | Method for efficiently inducing human cells to reprogram into neuron cells in vitro |
CN202310394178.8A Pending CN116162591A (en) | 2021-03-26 | 2021-03-26 | Method for efficiently inducing human cells to reprogram into neuron cells in vitro |
CN202310394172.0A Pending CN116218774A (en) | 2021-03-26 | 2021-03-26 | Method for efficiently inducing human cells to reprogram into neuron cells in vitro |
CN202310394174.XA Pending CN116286643A (en) | 2021-03-26 | 2021-03-26 | Method for efficiently inducing human cells to reprogram into neuron cells in vitro |
CN202310394176.9A Pending CN116144596A (en) | 2021-03-26 | 2021-03-26 | Method for efficiently inducing human cells to reprogram into neuron cells in vitro |
CN202110326257.6A Active CN113278585B (en) | 2021-03-26 | 2021-03-26 | Method for in vitro induction of reprogramming of human cells into neuron cells |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310394175.4A Pending CN116179489A (en) | 2021-03-26 | 2021-03-26 | Method for efficiently inducing human cells to reprogram into neuron cells in vitro |
CN202310394178.8A Pending CN116162591A (en) | 2021-03-26 | 2021-03-26 | Method for efficiently inducing human cells to reprogram into neuron cells in vitro |
CN202310394172.0A Pending CN116218774A (en) | 2021-03-26 | 2021-03-26 | Method for efficiently inducing human cells to reprogram into neuron cells in vitro |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310394176.9A Pending CN116144596A (en) | 2021-03-26 | 2021-03-26 | Method for efficiently inducing human cells to reprogram into neuron cells in vitro |
CN202110326257.6A Active CN113278585B (en) | 2021-03-26 | 2021-03-26 | Method for in vitro induction of reprogramming of human cells into neuron cells |
Country Status (1)
Country | Link |
---|---|
CN (6) | CN116179489A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116103343A (en) * | 2022-11-16 | 2023-05-12 | 广西壮族自治区人民医院 | Method for efficiently inducing human cells to reprogram into functional neurons by over-expressing SMAD3 gene |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101229536B1 (en) * | 2009-03-24 | 2013-02-04 | (주)마리아 바이오텍 | A method for Regenerating Dopaminergic neurons in Substantia nigra pars compacta using adult stem cells or progenitor cells |
CN105331634B (en) * | 2014-08-08 | 2018-11-27 | 中国科学院动物研究所 | A kind of induced fibroblast transdifferentiation is the method and its application of neuronal cell |
CN105039258B (en) * | 2015-07-03 | 2018-04-17 | 北京大学 | Method and composition by non-neuronal cell reprogramming for neuron cell |
CN106337037A (en) * | 2015-07-08 | 2017-01-18 | 中国科学院上海生命科学研究院 | Medicinal composition for inducing direct conversion of fibroblasts into nerve cells, and use of medicinal composition |
WO2018160028A1 (en) * | 2017-03-02 | 2018-09-07 | 주식회사 셀라토즈테라퓨틱스 | Medium composition for neuron differentiation and method for differentiating somatic cells into neurons using same medium composition |
WO2018187428A1 (en) * | 2017-04-04 | 2018-10-11 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | A modified cell culture medium and uses thereof |
EP3652200A4 (en) * | 2017-07-13 | 2021-04-28 | Allele Biotechnology And Pharmaceuticals, Inc. | Induction of neural progenitor cells, oligodendrocyte progenitor cells, and oligodendrocytes by stem cell differentiation using landmark transcription factors |
CN107723273A (en) * | 2017-10-27 | 2018-02-23 | 广西大学 | A kind of preparation method of the induction goat multipotential stem cell of micromolecular compound completely |
CN110408594A (en) * | 2019-07-31 | 2019-11-05 | 吉林大学 | A method of human fibroblasts are efficiently largely reprogrammed as mature neuron |
CN110804593B (en) * | 2019-10-17 | 2021-09-03 | 苏州大学 | Small molecular compound combination for inducing skin fibroblast to directly transdifferentiate towards neuron and application |
CN110951673B (en) * | 2019-12-20 | 2022-04-22 | 广西大学 | Method for inducing transdifferentiation of somatic cells into mammary epithelial cells in vitro by using small molecular compound |
CN112608904B (en) * | 2020-12-30 | 2023-02-07 | 滨州医学院 | Method for efficiently and rapidly reprogramming somatic cells into neural stem cells and application thereof |
-
2021
- 2021-03-26 CN CN202310394175.4A patent/CN116179489A/en active Pending
- 2021-03-26 CN CN202310394178.8A patent/CN116162591A/en active Pending
- 2021-03-26 CN CN202310394172.0A patent/CN116218774A/en active Pending
- 2021-03-26 CN CN202310394174.XA patent/CN116286643A/en active Pending
- 2021-03-26 CN CN202310394176.9A patent/CN116144596A/en active Pending
- 2021-03-26 CN CN202110326257.6A patent/CN113278585B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN113278585A (en) | 2021-08-20 |
CN116144596A (en) | 2023-05-23 |
CN116179489A (en) | 2023-05-30 |
CN116162591A (en) | 2023-05-26 |
CN116218774A (en) | 2023-06-06 |
CN113278585B (en) | 2023-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104894060B (en) | Inducing somatic transdifferentiation is the method and its application of neural stem cell | |
WO2022135279A1 (en) | Use of myog gene as target in preparation of drug for treating cardiovascular diseases associated with myocardial apoptosis | |
CN104762324B (en) | Method using Runx2 and micromolecular compound induction human fibroblasts reprogramming for Gegenbaur's cell | |
KR20120002134A (en) | Method for dedifferentiations of adipose tissue stromal cells | |
CN113278585B (en) | Method for in vitro induction of reprogramming of human cells into neuron cells | |
KR101982801B1 (en) | Composition for inducing differentiation to retinal pigment epithelium | |
CN114645061B (en) | SmMYB76 gene and application thereof in improving salvianolic acid content in salvia miltiorrhiza bunge | |
Edamura et al. | Recombinant canine basic fibroblast growth factor-induced differentiation of canine bone marrow mesenchymal stem cells into voltage-and glutamate-responsive neuron-like cells | |
CN112626075B (en) | Cloning primer, function and application of SmAP2/ERF152 gene for regulating and controlling tanshinone synthesis | |
CN101418285A (en) | Method for inducing hepatic oval cells differentiation to bile duct cells and its special culture medium | |
US20240034991A1 (en) | Method for efficiently inducing reprogramming of human cell into neuronal cell | |
CN112301038B (en) | Ginseng WRKY64-04 gene and application thereof | |
CN111592585A (en) | Application of UL16 protein in preparation of drugs for promoting cell mitochondrial function | |
CN109679960B (en) | siRNA of gene RGD1559786 for regulating hepatocyte proliferation and application thereof | |
KR20120134360A (en) | Composition for improving dedifferentiation of cells and method for producing induced pluripotent stem cells | |
Yang et al. | Establishment of recombinant Catharanthus roseus stem cells stably overexpressing ORCA4 for terpenoid indole alkaloids biosynthesis | |
CN113528576A (en) | Recurrent grapevine patient specific induced pluripotent stem cell line containing NLRP7 pure and mutant and construction method thereof | |
CN116445410A (en) | Method for regulating and controlling differentiation of neural stem cells and biological product used by method | |
CN114181915B (en) | Application of bioactive polypeptide synthesized based on KDM2B sequence in neural differentiation and regeneration repair of mesenchymal stem cells | |
KR100952959B1 (en) | A method of asiaticoside production from Centella asiatica L. Urban hairy roots | |
CN115054612B (en) | Enhancer capable of promoting bone formation and application thereof | |
CN111662876B (en) | Method for inducing human fibroblast to reprogram to Leydig-like cell | |
CN110628824B (en) | Construction method and application of DJ-1 function-loss cell model | |
Tang et al. | Wnt Signaling Promotes Cell Caudalization And Inner Ear Differentiation in Mouse Stem Cell-Derived Organoids | |
CN116103343A (en) | Method for efficiently inducing human cells to reprogram into functional neurons by over-expressing SMAD3 gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |